Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022

Authors:

Abstract
During January 2022 when the incidence of COVID-19 in the United States was at its highest, 82% of intensive care unit hospital beds were occupied, and nearly 900 000 COVID–19-related deaths had occurred since the pandemic began.1,2 Older adults and persons with underlying medical conditions such as chronic kidney disease, diabetes, and obesity are at increased risk for severe outcomes including hospitalization or death.3 Several neutralizing monoclonal antibodies and antivirals directed at SARS-CoV-2 have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for treatment of persons with mild to moderate COVID-19 who are at high risk for progression to severe disease.4-8 Most recently, these include EUA for nirmatrelvir boosted with ritonavir and molnupiravir in late December 2021 and remdesivir for outpatient use in January 2022. Although these therapies have been demonstrated in clinical trials to be effective in reducing the short-term risk of hospitalization or death among unvaccinated individuals,9-12 early limited drug supply, the requirement for prompt recognition of symptomatic disease and linkage to treatment, logistical barriers to administration, and the need for clinician and public awareness of therapeutic options have hampered widespread use.13,14 To date, use of outpatient SARS-CoV-2 pharmacotherapies in the US has not been well described.
All Related Versions

This publication has 17 references indexed in Scilit: